CITUS kicks-off entrepreneurial journey with a financial boost

With a mission to improve skin monitoring through mechanical characterization, Dübendorf-based medtech startup CITUS is developing a solution for more precise assessments of skin elasticity. Skin elasticity plays a pivotal role in guiding treatment strategies and evaluating the effectiveness of skincare products. Existing methods often fall short in terms of sensitivity and objectivity, leading to inaccuracies and substantial healthcare costs. CITUS introduces NIMBLEeva, a medical device designed to deliver a reliable, objective, and user-friendly tool of measuring skin elasticity. With solutions such as these, CITUS seeks to bridge the worlds of mechanics and medicine, driving advancements in healthcare, personalized treatments, and cosmetic procedures.

The startup has now closed its first convertible loan agreement with a total of CHF 375’000, together with the Health Innovation Hub of University Hospital Zurich, an incubator dedicated to supporting startups and entrepreneurship in healthcare, sharing CITUS' goal of accelerating innovative healthcare solutions for the improvement of patients' lives. Further investors include CADFEM, a simulation software and support provider active in the medical field and evoleen AG, an eHealth company builder that specializes in assisting global pharmaceutical and medtech firms in developing, accelerating, and enhancing their digital health businesses. S2S Ventures, a student-run venture capital fund founded in 2021, rounds out the investor group. Their mission is to guide early-stage entrepreneurs and SMEs, offering not just financial support but also hands-on operational assistance.

The convertible loan funds will support CITUS in advancing laboratory device certification and entering the European skin research market. Future milestones include further developing the NIMBLEeva device for diagnostics and preparing for a Seed investment round expected to conclude in March 2024.


(SR)